GlaxoSmithKline PLC (GSK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

GlaxoSmithKline PLC (GSK)

49.90

+0.01 (0.01%)

as of Sep 4, 2026, 7:59:56 pm Market Open.

82 watching

Investor Insights

Sep 7, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

GlaxoSmithKline PLC (GSK) is highlighted as a top investment pick by Stockchase Research Editor Michael O'Reilly, demonstrating resilience in the healthcare sector amidst market volatility. The company's recent earnings growth of 7% is notable, with financial metrics showing it trades at an appealing 11x earnings and 5.6x book value, alongside a robust return on equity (ROE) of 43%. Analysts have targeted a price of $54.31 for GSK, suggesting further upside potential with a recommended stop-loss strategy in light of ongoing disciplined investment practices. With a dividend yield of 3.3%, it continues to attract interest from investors looking for stability and growth potential in the pharmaceutical industry.

Consensus

Positive

Valuation

Undervalued

Similar

Pfizer, PFE

RISKY

Great dividend yield of 6.3%, trades at only 10x earnings. Cheap, you can own it here. Grew vaccine business. New CEO shed some divisions, so now more of a pure pharma company, which has risks. Have to worry about pipeline constantly. JNJ, for example, is more diversified, and that's what he prefers.

DON'T BUY

It's been successfully recently, but they have to pay for their drug pipeline which looks reasonable. Not cheap, but no drug is coming to market that will do very well. So-so overall. There are better peers.

PAST TOP PICK

(A Top Pick Mar 04/20, Down 9%)

Still likes it. They spun off over-the counter and consumer pharmaceuticals like Advil and that's when shares dipped (last fall). He chose it back then to bet on Covid vaccines, but that didn't pan out. But he likes it for that spin off and you get paid a reasonable dividend.

DON'T BUY

Not expensive, 10x earnings. Be careful with pharma, look at the pipeline. Focusing on one area, and that's the risk. Volatility as drugs come off patent. Lots of restructuring. He owns JNJ instead with its 3 businesses. Yield over 5%.

Unspecified

It has re-structured and is selling off some of its personal care business, thereby concentrating more on the pharmaceutical side. Not expensive and has a dividend yield over 6%.

BUY

They're spinning off their consumer products division, so GSK has historically traded at a discount with slower growth than other drugmakers. New management has turned around the pharmaceuticals side and make good consumer products. Aging populations in the west is a tailwind.

DON'T BUY

Large pharmaceutical company. Business model challenging since large investment required to produce new products. Good company, but owns other names in the space.

BUY

Options trading He jumped on some options. He likes healthcare and is adding to the sector. he doing call buying with Glaxo, not stock buying. There's a lot of activity here.

BUY

In 2018, they planned to merge their consumer health business with Pfizer's consumer to create a powerhouse, and planned to spin off this unit in three years. Last summer they offered an update--everyone expects a big cut to their 5% dividend yield, but cut it by only 31%. Management also offered encouraging sales projections. A hedge fund wants to bring in new leadership; he's unsure of this, but these types of move tend to prod management to deliver for shareholders, which is another reason to like this. He sees 10% upside.

BUY

Pays a 5% yield. It's doing okay. Okay to own for income.

DON'T BUY

A tough sector. Low growth, low PE, high dividend, pricing issues. Whole sector is struggling to come up with new drugs. Activist investor is probably pushing to break up the company; not good for long-term shareholders, though the share price would pop. Yield is about 6%.

COMMENT

The yield isn't safe. He truly wants GSK to do well and hopes their new vaccine with Sanopi works. Right now, GSK stock is up because of activists. Otherwise, shares will head down. He's less a fan of this now. Be prepared to take money off the table if the vaccine doesn't pan out.

BUY

Pharma has really not participated in rallies. In the last couple days, we have started to see some movement, like Pfizer. It is an area that will eventually be discovered. There is decent growth, nice dividends, but it lacks excitement. Nice to have one or two. It could be one of them.

HOLD

A big disappointment. He had hoped GSK could collaborate with another company on a vaccine, but he's been wrong. Sorry. Don't sell it with its 7% yield, but don't buy.

BUY

1-year outlook They've had a very good year like all pharmas, even in an election year. Pays a great yield and trades at a low multiple. Driving this are their COVID-19 vaccine efforts. They recently did a deal that puts them in MNRA which allows the fast-tracking of developing vaccines. This whole sector will continue to do well. The FDA has loosened rules to fast-track a COVID drug which he expects will lead to an effective result.

Showing 16 to 30 of 110 entries

Most Recent Experts

Kevin Simpson

Capital Wealth Planning

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brian Madden

First Avenue Investment Counsel

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

GlaxoSmithKline PLC (GSK)